Screener
Emergent Biosolutions EBS Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Emergent Biosolutions in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Emergent Biosolutions’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 5, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001367644-26-000082
FAQ
- What is Emergent Biosolutions's cash & equivalents?
- Emergent Biosolutions (EBS) reported cash & equivalents of $140.9M in Q2 2026.
- How has Emergent Biosolutions's cash & equivalents changed year-over-year?
- Emergent Biosolutions's cash & equivalents decreased by 48.0% year-over-year, from $271M to $140.9M.
- What is the long-term trend for Emergent Biosolutions's cash & equivalents?
- Over 5 years (2020 to 2025), Emergent Biosolutions's cash & equivalents has grown at a -19.6% compound annual growth rate (CAGR), from $621.5M to $209.1M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Emergent Biosolutions's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude